Blue Cross Blue Shield/Blue Care Network of Michigan
Medication Authorization Request Form

Blue Cross Blue Shield Blue Care Network of Michigan

Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

This form is to be used by participating physicians to obtain coverage for **drugs covered under the medical benefit**. For commercial members only, please complete this form and submit via fax to 1-877-325-5979. If you have any questions regarding this process, please contact BCBSM Provider Relations and Servicing or the Medical Drug Helpdesk at 1-800-437-3803 for assistance.

PATIENT INFORMATION		PHYSICIAN INFORMATION
Name		**Name**
ID Number		**Specialty**
D.O.B.	_____/_____/_____ MM/DD/YYYY ❑Male ❑Female	**Address**
Diagnosis		**City /State/Zip**
Drug Name	**Simponi Aria**	**Phone:** **Fax:**
Dose and Quantity		**NPI**
Directions		**Contact Person**
Date of Service(s)		**Contact Person** **Phone / Ext.**

STEP 1: DISEASE STATE INFORMATION

Required Demographic Information:

Patient Weight: _____*kg*

*Patient Height:*_____*ft* _____*inches*

Will the provider be administering the medication to the FEP member within the health plan's geographic service area?

❑ Yes ❑ No *If No, a prior authorization is not required through this process*.

Prior authorizations are required for FEP members that will be serviced by a provider within the health plan's geographic service area. If you are not a provider in the geographic service area, please contact the health plan for questions regarding the FEP member's benefit requirements.

Is this member's FEP coverage primary or secondary coverage?

❑ If primary, continue with question set.

❑ If secondary, **an authorization is not needed through this process. Please contact the member's primary coverage for determination of benefit and additional information.**

Site of Care:

A. At what location will the member be receiving the requested medication?

❑ Physician's office, home infusion, non-hospital affiliated ambulatory infusion center.

❑ Outpatient hospital infusion center. Please provide the name of the infusion center and rationale why the patient must receive this medication in a hospital outpatient setting. _____

_____

❑ Other. Please specify. _____

Criteria Questions:

1. Has the patient been on Simponi ARIA therapy continuously for the last **6 months**, excluding samples? ***Please select answer below:***
   - ❑ **YES** – this is a PA renewal for **CONTINUATION** of therapy, please answer the questions on **continucation section**:
   - ❑ **NO** – this is **INITIATION** of therapy, please answer the following questions:

2. What is the patient's diagnosis?

   ❑ Ankylosing Spondylitis (AS) (axial spondyloarthritis)
   a. Is the patient's ankylosing spondylitis active? ❑Yes ❑No
   b. Has the patient had either an inadequate response or intolerance to at least two different NSAIDs over a four-week period in total at maximum recommended or tolerated dose? ❑Yes ❑No*
   If NO, does the patient have a contraindication to NSAIDs? ❑Yes ❑No
   c. Does the prescriber agree to administer Simponi Aria within the FDA labeled maintenance dose of 2mg/kg IV every eight weeks? ❑Yes ❑No

   ❑ Polyarticular Juvenile Idiopathic Arthritis (pJIA)
   a. Does the patient have a contraindication to or have they had either an inadequate response or intolerance to a three-month trial of at least one conventional disease-modifying antirheumatic drug (DMARD)? ❑Yes ❑No
   b. Does the prescriber agree to administer Simponi Aria within the FDA labeled maintenance dose of 80 mg/m^2 (based on body surface area) every eight weeks? ❑Yes ❑No

   ❑ Psoriatic Arthritis (PsA)
   a. Is the patient's psoriatic arthritis active? ❑Yes ❑No
   b. Does the patient have a contraindication to or have they had either an inadequate response or intolerance to a three month trial of at least one conventional disease-modifying antirheumatic drug (DMARD)? ❑Yes ❑No
   c. Does the prescriber agree to administer Simponi Aria within the FDA labeled maintenance dose of 2mg/kg IV every eight weeks? ❑Yes ❑No

   ❑ Rheumatoid Arthritis (RA)
   a. Is the rheumatoid arthritis moderately to severely active? ❑Yes ❑No
   b. Does the patient have a contraindication to or have they had either an inadequate response or intolerance to a three month trial of at least one conventional disease-modifying antirheumatic drug (DMARD)? ❑Yes ❑No
   c. Does the patient have a contraindication to or have they had an intolerance to methotrexate (MTX)? ❑Yes ❑No*
   If NO, will Simponi Aria be used in combination with methotrexate? ❑Yes ❑No
   d. Does the prescriber agree to administer Simponi Aria within the FDA labeled maintenance dose of 2mg/kg IV every eight weeks? ❑Yes ❑No

   ❑ Other diagnosis **(*please specify*)**: _____

3. Does the patient have a contraindication to or have they had either an inadequate response or intolerance to a biologic *DMARD or targeted synthetic DMARD? ❑Yes ❑No

   DMARD includes: Actemra, Cimzia, Cosentyx, Enbrel, Entyvio, Humira, Ilumya, Inflectra, Kevzara, Kineret, Olumiant, Orencia, Otezla, Remicade, Renflexis, Rituxan, Rinvoq, Siliq, Simponi, Skyrizi, Stelara, Taltz, Tremfya, and Xeljanz

4. Has the patient had a recent test for a latent Tuberculosis (TB) infection? ❑Yes* ❑No
   If YES, what was the result of the TB test? ❑ Negative ❑ Positive*
   If POSITIVE, is the patient currently receiving treatment or has the patient already completed treatment for the TB infection? ❑Yes ❑No

5. Is the patient at risk for Hepatitis B Virus (HBV) infection? ❑Yes* ❑No
   If YES, has HBV been ruled out or has the patient already started treatment for the HBV infection? ❑Yes* ❑No
   If YES, please select answer below:
   ❑HBV been ruled out ❑Treatment has been initiation for HBV

6. Does the patient have any active infections including tuberculosis (TB) or Hepatitis B Virus (HBV) infection? ❑Yes ❑No

7. Will the patient be given live vaccines while on Simponi ARIA therapy? ❑Yes ❑No

8. Will Simponi ARIA be used in combination with any other biologic disease-modifying anti-rheumatic drug (DMARD)* or targeted synthetic DMARD? ❑Yes ❑No
   DMARD includes: Actemra, Cimzia, Cosentyx, Enbrel, Entyvio, Humira, Inflectra, Kevzara, Kineret, Orencia, Otezla, Remicade, Renflexis, Rituxan, Siliq, Stelara, Taltz, Tremfya, and Xeljanz

CONTINUATION OF SIMPONI ARIA THERAPY
(PA RENEWAL)

NOTE: Form must be completed in its **entirety** for processing

1. Has the patient been on Simponi ARIA therapy continuously for the last **6 months**, excluding samples? ***Answer below:***
   - ❑ **NO** – this is **INITIATION** of therapy, please answer the questions on **initiation section**
   - ❑ **YES** – this is a PA renewal for **CONTINUATION** of therapy, please answer the following questions:
2. What is the patient's diagnosis?
   - ❑ Ankylosing Spondylitis (AS) (axial spondyloarthritis)
     a. Does the prescriber agree to administer Simponi Aria within the FDA labeled maintenance dose of 2mg/kg IV every eight weeks? ❑Yes ❑No
   - ❑ Polyarticular Juvenile Idiopathic Arthritis (pJIA)
     a. Does the prescriber agree to administer Simponi Aria within the FDA labeled maintenance dose of 80 mg/m^2 (based on body surface area) every eight weeks? ❑Yes ❑No
   - ❑ Psoriatic Arthritis (PsA)
     a. Does the prescriber agree to administer Simponi Aria within the FDA labeled maintenance dose of 2mg/kg IV every eight weeks? ❑Yes ❑No
   - ❑ Rheumatoid Arthritis (RA)
     a. Does the patient have a contraindication to or have they had an intolerance to methotrexate (MTX)? ❑Yes ❑No*
     If NO, will Simponi Aria be used in combination with methotrexate? ❑Yes ❑No
     b. Does the prescriber agree to administer Simponi Aria within the FDA labeled maintenance dose of 2mg/kg IV every eight weeks? ❑Yes ❑No
   - ❑ Other diagnosis **(*please specify*)**: _____
3. Has the patient's condition improved or stabilized? ❑Yes ❑No
4. Does the patient have any active infections including tuberculosis (TB) or Hepatitis B Virus (HBV) infection? ❑Yes ❑No
5. Will the patient be given live vaccines while on Simponi ARIA therapy? ❑Yes ❑No
6. Will Simponi ARIA be used in combination with any other biologic disease-modifying anti-rheumatic drug (DMARD)* or targeted synthetic DMARD? ❑Yes ❑No

DMARD includes: Actemra, Cimzia, Cosentyx, Enbrel, Entyvio, Humira, Inflectra, Kevzara, Kineret, Orencia, Otezla, Remicade, Renflexis, Rituxan, Siliq, Stelara, Taltz, Tremfya, and Xeljanz

Chart notes are required for the processing of all requests. Please add any other supporting medical information necessary for our review **(required)**

Coverage will not be provided if the prescribing physician's signature and date are not reflected on this document.

❑ Request for expedited review: I certify that applying the standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain maximum function

Physician's Name	**Physician Signature**	**Date**
Step 2: Checklist	❑ Form Completely Filled Out ❑ Provide chart notes	❑ Attach test results
Step 3: Submit	**By Fax: BCBSM Specialty Pharmacy Mailbox** **1-877-325-5979**	**By Mail: BCBSM Specialty Pharmacy Program** **P.O. Box 312320, Detroit, MI 48231-2320**